Quarterly ResultMay 6, 2026, 04:14 PM
BioCryst Reports Q1 Net Loss of $721.8M Due to Astria Acquisition
AI Summary
BioCryst Pharmaceuticals reported a significant net loss of $721.8 million for Q1 2026, primarily due to a $697.8 million acquired in-process research and development expense related to its acquisition of Astria Therapeutics, Inc. Total revenues increased to $156.4 million from $145.5 million in the prior year. The company also secured a $400 million secured term loan during the quarter, contributing to an increase in cash and cash equivalents to $171.6 million. This led to a net loss per common share of $(2.98).
Key Highlights
- Acquisition of Astria Therapeutics, Inc. on January 23, 2026, resulted in a $697.8M acquired in-process R&D expense.
- Reported a net loss of $721.8M for Q1 2026, compared to a net income of $32k in Q1 2025.
- Total revenues increased to $156.4M in Q1 2026 from $145.5M in Q1 2025.
- Secured a $400M term loan, increasing total liabilities to $1.02B as of March 31, 2026.
- Cash and cash equivalents rose to $171.6M as of March 31, 2026, from $89.7M at December 31, 2025.
- Net loss per common share was $(2.98) for Q1 2026, compared to $0.00 in Q1 2025.
- Net cash used in operating activities was $(61.8M) in Q1 2026, up from $(27.5M) in Q1 2025.
- Total stockholders' deficit increased to $(553.8M) from $(119.2M) at December 31, 2025.